Abstract:Background: Drug resistance is one of the biggest challenges in cancer therapy. temozolomide (TMZ) represents the most important chemotherapeutic option for glioma treatment. However, the therapeutic efficacy of TMZ remains very limited due to its frequent resistance in glioma, and the underlying mechanisms were not fully addressed. Herein, we demonstrate that the elevated expression of CD147 contributes to TMZ resistance in glioma cells, potentially through the post-translational regulation of Nrf2 expression. Methods: Cell-based assays of CD147 triggered drug resistance were performed through Edu-incorporation assay, CCK8 assay, TUNEL staining assay and flow cytometric assay. Luciferase reporter assay, protein stability related assays, co-immunoprecipitation assay were used to determine CD147 induction of Nrf2 expression through β-TrCP dependent ubiquitin system. Finally, the effect of the CD147/Nrf2 signaling on glioma progression and TMZ resistance were evaluated by functional experiments and clinical samples. Results: Based on the analysis of clinical glioma tissues, CD147 is highly expressed in glioma tissues and positively associated with tumor malignancy. Suppression of CD147 expression increased the inhibitory effect of TMZ on cell survival in both U251 and T98G cells, whereas the gain of CD147 function blocked TMZ-induced ROS production and cell death. Mechanistic study indicates that CD147 inhibited GSK3β/β-TrCP-dependent Nrf2 degradation by promoting Akt activation, and subsequently increased Nrf2-mediated anti-oxidant gene expressions. Supporting the biological significance, the reciprocal relationship between CD147 and Nrf2 was observed in glioma tissues, and associated with patient outcome. Conclusions: Our data provide the first evidence that glioma resistance to TMZ is potentially due to the activation of CD147/Nrf2 axis. CD147 promotes Nrf2 stability through the suppression of GSK3β/β-TrCP dependent Nrf2 protein degradation, which results in the ablation of TMZ induced ROS production. As such, we point out that targeting CD147/Nrf2 axis may provide a new strategy for the treatment of TMZ resistant gliomas.

TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

TRIM31 Enhances Chemoresistance in Glioblastoma Through Activation of the PI3K/Akt Signaling Pathway

Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis

The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma

Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner

TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO

TRIM31 Promotes Glioma Proliferation and Invasion Through Activating NF-κB Pathway.

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide

TRIM56 Promotes Malignant Progression of Glioblastoma by Stabilizing Ciap1 Protein.

Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma

TRIM21 Overexpression Promotes Tumor Progression by Regulating Cell Proliferation, Cell Migration and Cell Senescence in Human Glioma.

TRIM14 Promotes Chemoresistance in Gliomas by Activating Wnt/β-catenin Signaling Via Stabilizing Dvl2

TRIM27 promotes the Warburg effect and glioblastoma progression via inhibiting the LKB1/AMPK/mTOR axis

TRIM7 Modulates NCOA4-mediated Ferritinophagy and Ferroptosis in Glioblastoma Cells

TRIM22 activates NF-B signaling in glioblastoma by accelerating the degradation of IB

CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway

A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

TRIM25 Regulates Oxaliplatin Resistance in Colorectal Cancer by Promoting EZH2 Stability

TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα